Canadá - inglês - Health Canada

bristol-myers squibb canada - asunaprevir - capsule - 100mg - asunaprevir 100mg - hcv protease inhibitors

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - asunaprevir 100mg - capsule - 100 mg - active: asunaprevir 100mg excipient: butylated hydroxytoluene gelatin glycerol glycerol monocaprylocaprate(type i) sorbitol sorbitan solution medium-chain triglycerides opacode black nsp-78-17827 polysorbate 80 purified water titanium dioxide - indicated in combination with other medicinal products for the treatment of chronic hepatitis c virus (hcv) infection in adults with compensated liver disease (including cirrhosis)

União Europeia - inglês - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir sodium, lamivudine - hiv infections - antivirals for systemic use - dovato is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Israel - inglês - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; dolutegravir as sodium; lamivudine - film coated tablets - dolutegravir as sodium 50 mg; abacavir as sulfate 600 mg; lamivudine 300 mg - lamivudine and abacavir and dolutegravir - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults and adolescents above 12 years of age weighing at least 40 kg.before initiating treatment with abacavir-containing products, screening for carriage of the hla-b*5701 allele should be performed in any hiv-infected patient, irrespective of racial origin. abacavir should not be used in patients known to carry the hla-b*5701 allele.

Israel - inglês - Ministry of Health

glaxo smith kline (israel) ltd - dolutegravir as sodium; lamivudine - film coated tablets - lamivudine 300 mg; dolutegravir as sodium 50 mg - lamivudine and dolutegravir - dovato is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine and viral load ≤500,000 c/ml.

Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome s.a. - dolutegravir (dolutegravir sodium), abacavir (abacavir sulfate), lamivudine - tablets film-coated - 50mg+ 600mg+ 300mg

Malta - inglês - Medicines Authority

sanofi malta limited - amiodarone hydrochloride - solution for injection - amiodarone hydrochloride 150 milligram(s) - cardiac therapy

Malta - inglês - Medicines Authority

sanofi malta limited - amiodarone hydrochloride - tablet - amiodarone hydrochloride 200 milligram(s) - cardiac therapy

Canadá - inglês - Health Canada

janssen inc - simeprevir (simeprevir sodium) - capsule - 150mg - simeprevir (simeprevir sodium) 150mg - hcv protease inhibitors

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - abacavir sulfate 702mg equivalent to abacavir 600 mg;  ; dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg;  ;  ;  ; lamivudine 300mg;   - film coated tablet - 50mg/600mg/300mg - active: abacavir sulfate 702mg equivalent to abacavir 600 mg   dolutegravir sodium 52.6mg equivalent to dolutegravir 50 mg       lamivudine 300mg   excipient: magnesium stearate mannitol microcrystalline cellulose opadry purple 85f90057 povidone sodium starch glycolate - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in triumeq.